focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 12th Mar 2014 09:03

Ashtead Group: Citi raises target price from 850p to 1075p keeping a buy recommendation.Barratt Developments: Goldman Sachs reduces target price from 527p to 502p and downgrades to neutral.British Land: Jefferies downgrades to hold with a target price of 707p.Brooks Macdonald Group: Canaccord Genuity increases target price from 1620p to 1780p, but downgrades from buy to hold.Brown (N) Group: UBS lowers target price from 565p to 535p and downgrades from neutral to sell.Cape: Canaccord Genuity ups target price from 300p to 360p maintaining a buy recommendation.Close Brothers Group: Berenberg raises target price from 1330p to 1640p and maintains a buy recommendation. JP Morgan increases target price from 1357p to 1480p and stays with its overweight rating. UBS raises target price from 1340p to 1420p maintaining a neutral rating.Countrywide: Goldman Sachs ups target price from 748p to 764p, while downgrading to neutral.Craneware: Investec raises target price from 615p to 645p keeping a buy recommendation.Crest Nicholson Holdings: Goldman Sachs shifts target price from 525p to 530p and upgrades to strong buy.esure Group: Deutsche Bank moves target price from 300p to 313p and keeps a buy recommendation. Citi shifts target price from 291p to 294p retaining a buy recommendation. Canaccord Genuity lowers target price from 305p to 295p maintaining its buy recommendation.Fenner: Jefferies lowers target price from 505p to 490p, while staying with its buy recommendation. Espirito Santo cuts target price from 410p to 400p and retains its neutral rating. UBS cuts target price from 500p to 480p leaving its buy recommendation unaltered.Go-Ahead Group: Deutsche Bank increases target price from 1640p to 2100p, while downgrading to hold. RBC Capital raises target price from 1800p to 2300p keeping its neutral rating.Hangar8: Westhouse Securities takes target price from 270p to 310p, but downgrades to add.Hikma Pharmaceuticals: Panmure Gordon ups target price from 1375p to 1400p, while downgrading from buy to hold.Hummingbird Resources: Cantor Fitzgerald moves target price from 68p to 80p leaving its buy recommendation unchanged.Hunting: Investec ups target price from 830p to 890p, but downgrades from buy to hold.IFG Group: N+1 Singer upgrades to buy with a target price of 150p.IMI: RBC Capital cuts target price from 1600p to 1550p and retains an outperform rating. Espirito Santo raises target price from 1530p to 1650p and upgrades to buy.Inchcape: Deutsche Bank ups target price from 655p to 685p and reiterates its hold recommendation. Nomura takes target price from 580p to 600p and maintains its neutral rating.Inmarsat: Jefferies moves target price from 790p to 800p and retains a buy recommendation.International Consolidated Airlines Group: Liberum Capital takes target price from 450p to 550p and keeps a buy recommendation.Kazakhmys: UBS raises target price from 210p to 300p and maintains a neutral rating.Land Securities: Jefferies downgrades to hold with a target price of 1112p.Merlin Entertainment: JP Morgan moves target price from 415p to 430p and maintains an overweight rating.Modern Water: Numis cuts target price from 77p to 62p, while its buy recommendation remains unchanged.Morgan Advanced Materials: Espirito Santo raises target price from 280p to 320p and retains a neutral rating.Persimmon: Goldman Sachs cuts target price from 1892p to 1840p and downgrades from strong buy to buy.Phoenix IT: Panmure Gordon lowers target price from 144p to 136p, while upgrading from hold to buy.Plethora Solutions: Daniel Stewart moves shifts target price from 18.9p to 25.6p and keeps a buy recommendation.Premier Farnell: UBS lowers target price from 240p to 235p and stays with its neutral rating.Redrow: Goldman Sachs raises target price from 341p to 423p upgrading to buy.Rentokil Initial: Credit Suisse ups target price from 95p to 125p and keeps a neutral rating.Rightmove: Goldman Sachs reduces target price from 4360p to 3607p and downgrades from strong buy to buy.Rockhopper Exploration: Canaccord Genuity reduces target price from 345p to 265p, but stays with its buy recommendation.Rotork: Espirito Santo increases target price from 2500p to 2600p and stays with its neutral rating.Servelec Group: Investec raises target price from 284p to 310p and maintains its buy recommendation.Spirax-Sarco Engineering: Espirito Santo raises target price from 3000p to 3200p and reiterates a neutral rating.Travis Perkins: Berenberg cuts target price from 1880p to 1800p and retains a hold recommendation.Tyman: Numis raises target price from 285p to 320p reiterating an add rating.WEIR Group: Espirito Santo raises target price from 2600p to 2800p and maintains a buy recommendation.
More News
13 Jul 2010 07:28

Plethora Solutions Sees 1H In Line With Market Views, Revenue GBP1M

LONDON (Dow Jones)--Plethora Solutions Holdings PLC (PLE.LN), the U.K.-based specialty pharmaceutical company, said Tuesday first half earnings are expected to be in line with analyst expectations with revenue for the six months ended June 30 of GBP1.0 million and of GBP1.4 million. MAIN FACTS:

Read more
30 Jun 2010 09:30

UK SMALLCAP ROUNDUP: Scott Wilson Bidder URS Gets Deadline

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps SCOTT WILSON GROUP PLC (SWG.LN), a U.K. engineering consultant, Wednesday said its board will give its recommendation to shareholders on the company's bi

Read more
30 Jun 2010 07:48

Plethora Solutions Gets GBP1 Mln Loan For Urology Business

LONDON (Dow Jones)--Drug company Plethora Solutions Holdings PLC (PLE.LN) Wednesday said it has agreed a GBP1 million, five-year secured term loan from a government fund which will be used to speed the roll-out of its specialty pharmaceutical business. The firm said The Urology Company, which it

Read more
5 May 2010 12:52

Small caps round-up: Global Brands, Japan Leisure, Plethora...

Shares in Global Brands charged forward as the Domino's Pizza franchise holder in Switzerland reported strong trading in 2010 to follow a good end to 2009. Global says January sales increased 7.4% on January 2009, February sales increased 11.2%, March sales increased 14.5% and April sales increased

Read more
9 Mar 2010 09:51

Small caps round-up: Ark Therapies, Pangea, Shore Capital ...

Shares in Ark Therapies fell back after the drug developer said it would consider approaches it has received following a recommendation that a further clinical trial would be needed before its brain cancer treatment Cerepro could be approved. Shares in Pangea Diamonds sparkled after the diamond pro

Read more
30 Nov 2009 07:37

Small caps round-up: SDI Group, First Property, Beowulf...

SDI swung into the black at the half-way stage, although the automated warehousing systems firm said the outlook remains "tough". There was a profit of £305,000 in the six months to 30 September versus a loss of £2.6m in the half year to 31 May 2008 (the year end has now moved from November to Marc

Read more
23 Nov 2009 13:17

Small cap round-up: Entertainment One, Plethora, Goldstone...

Film distributor Entertainment One reports record takings for the UK and Canadian opening of The Twilight Saga: New Moon, the sequel to the 2008 box office hit Twilight. New Moon, a film about vampires, has already generated an estimated weekend box office of more than £11m in the UK and $11m in C

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
29 Jul 2009 08:15

Plethora reports PSD502 trial success

Plethora Solutions has moved closer to global approval for its PSD502 premature ejaculation treatment for men after a final US phase 3 trial met all of its objectives. This study, involving patients from the US, Canada and Europe, was one of two pivotal Phase III studies for PSD502, which were run

Read more
26 May 2009 07:57

Plethora sells rights to key product

Drug developer Plethora has sold the rights of its key PSD502 premature ejaculation product to Sciele Pharma to cut its debts and pay back venture capital financing. Under the terms of the agreement, Sciele will make additional upfront payments of $8.4m and also share development costs for PSD502 f

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.